SCHEMBL8368468

SCHEMBL8368468

Bc1ncc(-c2ccccc2)c(OC)n1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SQOR Q9Y6N5 5/20 0.46
▸ KMT2A Q03164 3/20 0.46
▸ MAPT P10636 3/20 0.42
▸ CASP1 P29466 1/20 0.42
▸ KDM4E B2RXH2 5/20 0.42
▸ ALDH1A1 P00352 3/20 0.42
▸ NPC1 O15118 2/20 0.42
▸ RAB9A P51151 2/20 0.42
▸ SMN1; SMN2 Q16637 2/20 0.42
▸ MEN1 O00255 2/20 0.42
▸ HSD17B10 Q99714 3/20 0.41
▸ GAA P10253 1/20 0.41
▸ NPSR1 Q6W5P4 1/20 0.41
▸ NFKB1 P19838 1/20 0.40
▸ NFKB2 Q00653 1/20 0.40
▸ RELA Q04206 1/20 0.40
▸ PKM P14618 1/20 0.39
▸ EDNRA P25101 1/20 0.39
▸ ADORA1 P30542 2/20 0.38
▸ ADORA2A P29274 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3767625 0.81 QPCT (0.54) SQORKMT2AMAPTCASP1KDM4E
SCHEMBL24713444 0.71 SQOR (0.53) SQORKMT2AMAPTCASP1KDM4E
SCHEMBL11741475 0.71 NCOA1 (0.52) SQORKMT2AMAPTCASP1ALDH1A1
SCHEMBL30439186 0.70 MAPT (0.56) SQORKMT2AMAPTCASP1ALDH1A1
SCHEMBL20764961 0.70 MAPT (0.56) SQORKMT2AMAPTCASP1ALDH1A1
SCHEMBL30505741 0.69 SQOR (0.59) SQORKMT2AMAPTCASP1KDM4E
SCHEMBL29131667 0.69 SQOR (0.59) SQORKMT2AMAPTCASP1KDM4E
SCHEMBL27852466 0.69 SQOR (0.54) SQORKMT2AMAPTKDM4EALDH1A1
SCHEMBL6916456 0.69 ALOX5AP (0.51) SQORKMT2AMAPTCASP1ALDH1A1
SCHEMBL5912697 0.68 SQOR (0.45) SQORKMT2AMAPTCASP1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2003033671-A2 HUMAN GLUCAGON-LIKE-PEPTIDE-1 MIMICS AND THEIR USE IN THE TREATMENT OF DIABETES AND RELATED CONDITIONS BRISTOL-MYERS SQUIBB COMPANY (US) 2003-04-24 — — WO disclosed
Send feedback